<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434249</url>
  </required_header>
  <id_info>
    <org_study_id>PSC-DS BIGI</org_study_id>
    <nct_id>NCT03434249</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy of Bifidobacterium BB-12® in the Treatment of Infantile Colic</brief_title>
  <official_title>Studio Clinico Randomizzato Per Valutare l'Efficacia Del Bifidobacterium BB-12® Nel Trattamento Delle Coliche Infantili</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOFAR S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SOFAR S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double blind controlled study to investigate the effects
      of Bifidobacterium, BB-12® versus placebo in a study group of pediatric patients with
      infantile colic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2016</start_date>
  <completion_date type="Actual">November 6, 2017</completion_date>
  <primary_completion_date type="Actual">November 6, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective randomized double blind placebo controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Crying lenght</measure>
    <time_frame>28 days from the baseline</time_frame>
    <description>average length of time that babies spend crying each day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Crying episodes</measure>
    <time_frame>28 days from the baseline</time_frame>
    <description>daily number of crying episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regurgitation and Vomit episodes</measure>
    <time_frame>28 days from the baseline</time_frame>
    <description>daily number of regurgitation and vomit episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious diseases incidence</measure>
    <time_frame>28 days from the baseline</time_frame>
    <description>number of infections in respiratory system, gastrointestinal system, urinary tract and skin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel evacuation</measure>
    <time_frame>28 days from the baseline</time_frame>
    <description>daily frequency of bowel evacuation and fecal consistency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut Microbiota</measure>
    <time_frame>28 days from the baseline</time_frame>
    <description>Evaluation of changes in the gut microbiota composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>28 days from the baseline</time_frame>
    <description>Evaluation of calprotectin levels in fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-defensin type 2</measure>
    <time_frame>28 days from the baseline</time_frame>
    <description>Evaluation of Beta-defensin type 2 levels in fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LL37 peptide</measure>
    <time_frame>28 days from the baseline</time_frame>
    <description>Evaluation of LL37 peptide levels in fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short chain fatty acids</measure>
    <time_frame>28 days from the baseline</time_frame>
    <description>Evaluation of short chain fatty acids levels in fecal samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Infantile Colic</condition>
  <condition>Colic, Infantile</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium, BB-12® (Bifidolactis Infant)</intervention_name>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidolactis Infant Placebo</intervention_name>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are included in the study if they meet all the following criteria:

          -  Exclusively breastfed healthy infants of both sexes, aged ≤ 7 weeks.

          -  Diagnosis of IC according to Rome III criteria.

          -  Written informed consent of the parent/tutor.

        Exclusion Criteria:

        Patients are excluded from this study if they meet any of the following criteria:

          -  Birth weight &lt; 2500 g.

          -  Gestational age &lt; 37 weeks.

          -  APGAR 5 minutes &lt; 7.

          -  Formula feeding.

          -  Stunting/loss of weight (&lt; 100 g/weeks from birth to the last reported weight).

          -  Neurological diseases.

          -  Known or suspected food allergy.

          -  Gastroesophageal reflux disease.

          -  Use of substances that alter gut microbiota (probiotics, prebiotics, antibiotics,
             gastric acidity inhibitors) in the last 2 weeks prior the enrollment.

          -  History of fever and/or infectious diseases in the last 2 weeks prior to enrollment.

          -  Ongoing systemic infections.

          -  History of congenital infections.

          -  Chronic intestinal diseases (cystic fibrosis or other forms of primitive pancreatic
             insufficiency)

          -  Primitive or secondary malformations of the gastrointestinal tract (such as esophageal
             atresia, intestinal atresia, short bowel syndrome, malrotation).

          -  Metabolic diseases.

          -  Genetic diseases and chromosomal abnormalities.

          -  Primary or secondary immunodeficiencies.

          -  Not sufficient reliability or presence of conditions that may result in
             non-compliance/adherence of the patient to the Protocol.

          -  Previous participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Berni Canani, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento di Scienze Mediche Traslazionali - Sezione Pediatria - Università degli Studi di napoli &quot;Federico II&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hyman PE, Milla PJ, Benninga MA, Davidson GP, Fleisher DF, Taminiau J. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2006 Apr;130(5):1519-26. Review.</citation>
    <PMID>16678565</PMID>
  </reference>
  <reference>
    <citation>Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013 Feb;162(2):257-62. doi: 10.1016/j.jpeds.2012.08.004. Epub 2012 Sep 14.</citation>
    <PMID>22981952</PMID>
  </reference>
  <reference>
    <citation>Kabeerdoss J, Devi RS, Mary RR, Prabhavathi D, Vidya R, Mechenro J, Mahendri NV, Pugazhendhi S, Ramakrishna BS. Effect of yoghurt containing Bifidobacterium lactis Bb12® on faecal excretion of secretory immunoglobulin A and human beta-defensin 2 in healthy adult volunteers. Nutr J. 2011 Dec 23;10:138. doi: 10.1186/1475-2891-10-138.</citation>
    <PMID>22196482</PMID>
  </reference>
  <reference>
    <citation>Mohan R, Koebnick C, Schildt J, Mueller M, Radke M, Blaut M. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res. 2008 Oct;64(4):418-22. doi: 10.1203/PDR.0b013e318181b7fa.</citation>
    <PMID>18552710</PMID>
  </reference>
  <reference>
    <citation>Mohan R, Koebnick C, Schildt J, Schmidt S, Mueller M, Possner M, Radke M, Blaut M. Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. J Clin Microbiol. 2006 Nov;44(11):4025-31. Epub 2006 Sep 13.</citation>
    <PMID>16971641</PMID>
  </reference>
  <reference>
    <citation>Savino F, Cordisco L, Tarasco V, Calabrese R, Palumeri E, Matteuzzi D. Molecular identification of coliform bacteria from colicky breastfed infants. Acta Paediatr. 2009 Oct;98(10):1582-8. doi: 10.1111/j.1651-2227.2009.01419.x. Epub 2009 Jul 9.</citation>
    <PMID>19604166</PMID>
  </reference>
  <reference>
    <citation>Hall B, Chesters J, Robinson A. Infantile colic: a systematic review of medical and conventional therapies. J Paediatr Child Health. 2012 Feb;48(2):128-37. doi: 10.1111/j.1440-1754.2011.02061.x. Epub 2011 Apr 7. Review.</citation>
    <PMID>21470331</PMID>
  </reference>
  <reference>
    <citation>Savino F, Bailo E, Oggero R, Tullio V, Roana J, Carlone N, Cuffini AM, Silvestro L. Bacterial counts of intestinal Lactobacillus species in infants with colic. Pediatr Allergy Immunol. 2005 Feb;16(1):72-5.</citation>
    <PMID>15693915</PMID>
  </reference>
  <reference>
    <citation>Savino F, Cresi F, Pautasso S, Palumeri E, Tullio V, Roana J, Silvestro L, Oggero R. Intestinal microflora in breastfed colicky and non-colicky infants. Acta Paediatr. 2004 Jun;93(6):825-9.</citation>
    <PMID>15244234</PMID>
  </reference>
  <reference>
    <citation>Gupta SK. Is colic a gastrointestinal disorder? Curr Opin Pediatr. 2002 Oct;14(5):588-92. Review.</citation>
    <PMID>12352253</PMID>
  </reference>
  <reference>
    <citation>Lucassen PL, Assendelft WJ, van Eijk JT, Gubbels JW, Douwes AC, van Geldrop WJ. Systematic review of the occurrence of infantile colic in the community. Arch Dis Child. 2001 May;84(5):398-403. Review.</citation>
    <PMID>11316682</PMID>
  </reference>
  <reference>
    <citation>BRAZELTON TB. Crying in infancy. Pediatrics. 1962 Apr;29:579-88.</citation>
    <PMID>13872677</PMID>
  </reference>
  <reference>
    <citation>Iacovou M, Ralston RA, Muir J, Walker KZ, Truby H. Dietary management of infantile colic: a systematic review. Matern Child Health J. 2012 Aug;16(6):1319-31. doi: 10.1007/s10995-011-0842-5. Review.</citation>
    <PMID>21710185</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bifidobacterium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

